Saturday, June 16, 2018 8:37:54 AM
(Burlingame CA, United States - June 28-29, 2018)
ID: 4515269
Conference
Location: Burlingame CA, United States
2 Days
Compliance Online
Conference Dates: June 28-29, 2018
Stem cells harness the power to differentiate into numerous cells upon stimulation. This has led to their wide exploration across all of medicine, including high risk diseases. Of course, significant scientific breakthroughs in the use of stem cells to prevent, diagnose, and treat numerous diseases has caused numerous startup companies to form. Despite, such promise, the FDA has yet to approve stem cell therapies for a wide range of diseases, except cord bloodderived hematopoietic progenitor cells for certain indications.
This tutorial will provide an historical context for the use of stem cells in medicine, where the field has been and where it is going. It will also provide the few examples of FDA approved use of stem cells in medicine and what is needed for the field to progress. For example, in 2006, the U.S. FDA implemented regulations governing the use of human cells, tissues, and cellular and tissuebased products in humans including bone, ligament, skin, dura mater, stem cells, cartilage cells, and various other cellular and tissuebased products. Currently, there is an ongoing debate in industry on how such therapies should be regulated, in particular by the FDA or under the practice of medicine, under federal law or state law, and as drugs or simply biologics.
Learning Objectives:
Upon completing this course participants should have an understanding of:
1. Fundamentals of stem cells
What is all the excitement about
How to control stem cell differentiation
Sources of stem cells
Incorporating stem cells into biomaterials
Avoiding immune system clearance of stem cells
2. FDA regulatory approvals for the use of stem cells in medicine
Currently approved use of stem cells in medicine
FDA guidance documents for stem cell technologies
Global approval of stem cell technologies
How the FDA regulates regenerative treatments and therapies
The use of human cells, tissues, and cellular and tissuebased product criteria and “Minimal Manipulation Standard”
The drug and biological approval process
Regenerative products as medical devices
How to design appropriate clinical trials
Applicable good manufacturing and good laboratory practices
Product labeling, marketing and advertising
FDA and other federal agency enforcement action
3. Future thoughts on approaches for regulatory approval of stem cell technologies
Remaining hurdles
Outlook for new technologies
https://www.researchandmarkets.com/reports/4515269/fdas-regulation-of-regenerative-medicine
All posts are speculative and my opinion only. NOT investment advice.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM